Matches in UGent Biblio for { <https://biblio.ugent.be/publication/3139229#aggregation> ?p ?o. }
Showing items 1 to 42 of
42
with 100 items per page.
- aggregation classification "A1".
- aggregation creator B442105.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation date "2013".
- aggregation format "application/pdf".
- aggregation hasFormat 3139229.bibtex.
- aggregation hasFormat 3139229.csv.
- aggregation hasFormat 3139229.dc.
- aggregation hasFormat 3139229.didl.
- aggregation hasFormat 3139229.doc.
- aggregation hasFormat 3139229.json.
- aggregation hasFormat 3139229.mets.
- aggregation hasFormat 3139229.mods.
- aggregation hasFormat 3139229.rdf.
- aggregation hasFormat 3139229.ris.
- aggregation hasFormat 3139229.txt.
- aggregation hasFormat 3139229.xls.
- aggregation hasFormat 3139229.yaml.
- aggregation isPartOf urn:issn:0091-6749.
- aggregation language "eng".
- aggregation rights "I have transferred the copyright for this publication to the publisher".
- aggregation subject "Medicine and Health Sciences".
- aggregation title "Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma".
- aggregation abstract "Background: Adult patients with nasal polyps often have comorbid asthma, adding to the serious effect on the quality of life of these patients. Nasal polyps and asthma might represent a therapeutic challenge; inflammation in both diseases shares many features, such as airway eosinophilia, local IgE formation, and a T(H)2 cytokine profile. Omalizumab is a human anti-IgE mAb with proved efficacy in patients with severe allergic asthma. Omalizumab could be a treatment option for patients with nasal polyps and asthma. Objective: The goal of this study was to investigate the clinical efficacy of omalizumab in patients with nasal polyps and comorbid asthma. Methods: A randomized, double-blind, placebo-controlled study of allergic and nonallergic patients with nasal polyps and comorbid asthma (n = 24) was conducted. Subjects received 4 to 8 (subcutaneous) doses of omalizumab (n = 16) or placebo (n = 8). The primary end point was reduction in total nasal endoscopic polyp scores after 16 weeks. Secondary end points included a change in sinus computed tomographic scans, nasal and asthma symptoms, results of validated questionnaires (Short-Form Health Questionnaire, 31-item Rhinosinusitis Outcome Measuring Instrument, and Asthma Quality of Life Questionnaire), and serum/nasal secretion biomarker levels. Results: There was a significant decrease in total nasal endoscopic polyp scores after 16 weeks in the omalizumabtreated group (-2.67, P = .001), which was confirmed by means of computed tomographic scanning (Lund-Mackay score). Omalizumab had a beneficial effect on airway symptoms (nasal congestion, anterior rhinorrhea, loss of sense of smell, wheezing, and dyspnea) and on quality-of-life scores, irrespective of the presence of allergy. Conclusion: Omalizumab demonstrated clinical efficacy in the treatment of nasal polyps with comorbid asthma, supporting the importance and functionality of local IgE formation in the airways.".
- aggregation authorList BK771619.
- aggregation endPage "U166".
- aggregation issue "1".
- aggregation startPage "110".
- aggregation volume "131".
- aggregation aggregates 3139273.
- aggregation isDescribedBy 3139229.
- aggregation similarTo j.jaci.2012.07.047.
- aggregation similarTo LU-3139229.